Source: Healio News
In this video, Healio spoke with Farhad Ravandi, MD, about the promise of maintenance therapy in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.
Although maintenance therapy has been used in hematologic cancers for several decades in other diseases, such as myeloma, a lack of effective and relatively nontoxic agents stalled its use in AML. However, Ravandi said that new data have shown, for the first time, that maintenance therapy may be feasible in patients with AML.
Ravandi, professor of medicine and chief of the section of acute myeloid leukemia in the